Shares of CytRx plunged on the news that the FDA had halted a mid-stage trial for a drug to treat Lou Gehrig's disease. Regulators want to take some time to analyze results from animal studies of arimoclomol. CytRx stock was down 38 percent on a rough day. Release [1] | Report [2]
Links:
[1] http://www.fiercebiotech.com/press-releases/cytrx-provides-update-phase-iib-arimoclomol-clinical-trial-als
[2] http://money.cnn.com/news/newsfeeds/articles/apwire/48fcb25e75872c239a5853c2e02d8c10.htm